Replies to post #102624 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Good try to save on words.

Yes - the public release of pk/pd is immaterial but it first needs to be completed. Nearly every big and small pharma issues PR the pk/pd as it completes one key milestone in the process.

So as long as it is not declared - we know it is not complete.
So indirectly it is material.

[scottsmith]

It is highly material. Top of the food chain.

[kld2]

Okay, then, Missling can hold it as he wishes. Everyone on the board is playing Angel's Advocate. Let's be the Devil for a minute.

Let's say PK/PD data is not what the market wants to hear; there is no clear sub-group motherlode, no clear path ahead.

Let's also say 15-month is not the blooming rose everyone assumed. Rather, the budding rose has wilted.

So the good doctor says to himself: rather than release mediocre Ph2a data or PK/PD analysis (it looked good, but when we turned away and looked again at fifteen months, it looked less good) and watch the share price plummet, why not start the Rett's trial and, when the share price rises on hope, raise money for the Ph2b ALZ trial?

Who couldn't agree with that? One more assay, you never know what you might find. After all, there is much to mine in the mountain of the mind. (There might be a sleeping giant, wink, wink.) But you need money, capital.

[TomP1]

It is not immaterial when Missling has stated publicly on multiple occasions that it would be released when available.